Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease
- PMID: 9613726
- DOI: 10.1002/mds.870130303
Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease
Abstract
We have previously demonstrated that fetal nigral grafts can survive, reinnervate the striatum, and mediate clinically relevant recovery in a patient with Parkinson's disease (PD). Most previous autopsy cases have failed to identify meaningful numbers of viable grafted cells suggesting that differences in critical transplant variables determine graft viability. The present study evaluated the structural and functional correlates of fetal nigral transplantation in a second PD patient who received fetal nigral grafts according to our previously published transplant protocol. A 61-year-old woman with severe PD received bilateral fetal nigral grafts to the postcommissural putamen from seven donor fetuses (four right side and three left side) aged 6.5-9 weeks postconception. This patient died 19 months after surgery from a cause unrelated to the transplant surgery. Her postoperative clinical course was characterized by improved motor and activities of daily living scores during "off time," reduced "off time," and increased "on" time without dyskinesia. Positron emission tomography (PET) scans revealed a bilateral and progressive increase in fluorodopa (FD) uptake within the grafted putamen. Postmortem examination of the right hemisphere revealed large oval-shaped grafts containing more than 138,000 tyrosine-hydroxylase-immunoreactive (TH-ir) neurons. Grafted cells formed a seamless border with the host and provided dense TH-ir innervation to 78% of the host postcommissural putamen. Graft-mediated sprouting of host fibers was not observed. These data provide essential confirmation that, under appropriate transplant conditions, grafted nigral neurons can survive, reinnervate the host striatum, and provide clinical benefit to PD patients. These findings also support the concept that improved motor function and striatal FD uptake on PET after nigral grafting in PD are the result of the viability of grafted neurons and graft-derived reinnervation of the host striatum.
Similar articles
-
Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease.N Engl J Med. 1995 Apr 27;332(17):1118-24. doi: 10.1056/NEJM199504273321702. N Engl J Med. 1995. PMID: 7700284
-
Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies.J Comp Neurol. 1996 Jun 24;370(2):203-30. doi: 10.1002/(SICI)1096-9861(19960624)370:2<203::AID-CNE6>3.0.CO;2-6. J Comp Neurol. 1996. PMID: 8808731
-
Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease.Arch Neurol. 1999 Feb;56(2):179-87. doi: 10.1001/archneur.56.2.179. Arch Neurol. 1999. PMID: 10025423
-
Update on fetal transplantation: the Swedish experience.Mov Disord. 1998;13 Suppl 1:83-7. Mov Disord. 1998. PMID: 9613723 Review.
-
Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery.Exp Neurol. 1997 Mar;144(1):41-6. doi: 10.1006/exnr.1996.6386. Exp Neurol. 1997. PMID: 9126150 Review.
Cited by
-
Past, present, and future of cell replacement therapy for parkinson's disease: a novel emphasis on host immune responses.Cell Res. 2024 Jul;34(7):479-492. doi: 10.1038/s41422-024-00971-y. Epub 2024 May 22. Cell Res. 2024. PMID: 38777859 Free PMC article. Review.
-
Recent progress in the applications of presynaptic dopaminergic positron emission tomography imaging in parkinsonism.Neural Regen Res. 2025 Jan 1;20(1):93-106. doi: 10.4103/1673-5374.391180. Epub 2023 Dec 21. Neural Regen Res. 2025. PMID: 38767479 Free PMC article.
-
Efficacy and efficacy-influencing factors of stem cell transplantation on patients with Parkinson's disease: a systematic review and meta-analysis.Front Neurol. 2024 Apr 12;15:1329343. doi: 10.3389/fneur.2024.1329343. eCollection 2024. Front Neurol. 2024. PMID: 38682036 Free PMC article.
-
Cell-therapy for Parkinson's disease: a systematic review and meta-analysis.J Transl Med. 2023 Sep 7;21(1):601. doi: 10.1186/s12967-023-04484-x. J Transl Med. 2023. PMID: 37679754 Free PMC article.
-
Defining the unknowns for cell therapies in Parkinson's disease.Dis Model Mech. 2022 Oct 1;15(10):dmm049543. doi: 10.1242/dmm.049543. Epub 2022 Sep 27. Dis Model Mech. 2022. PMID: 36165848 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical